| 9.6 0 (0%) | 05-21 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 11.38 | 1-year : | 13.3 |
| Resists | First : | 9.75 | Second : | 11.38 |
| Pivot price | 9.47  |
|||
| Supports | First : | 9.36 |
Second : | 9.11 |
| MAs | MA(5) : | 9.62 |
MA(20) : | 9.43 |
| MA(100) : | 7.36 |
MA(250) : | 10.56  |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 74.6 |
D(3) : | 82 |
| RSI | RSI(14): 72.3 | |||
| 52-week | High : | 20.02 | Low : | 4.81 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ OPTN ] has closed below upper band by 22.8%. Bollinger Bands are 74.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 29 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 9.61 - 9.65 | 9.65 - 9.68 |
| Low: | 9.49 - 9.54 | 9.54 - 9.58 |
| Close: | 9.52 - 9.6 | 9.6 - 9.66 |
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It is also developing OPN-019 that combines liquid EDS device with an antiseptic. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2000 and is headquartered in Yardley, Pennsylvania.
Sat, 17 May 2025
OptiNose-Paratek Merger: What Shareholders Need to Know (OPTN, PRTK) - tradingcalendar.com
Fri, 21 Mar 2025
ProAssurance (PRA) and Optinose (OPTN) soar on M&A news - Investorsobserver
Fri, 21 Mar 2025
Further Upside For OptiNose, Inc. (NASDAQ:OPTN) Shares Could Introduce Price Risks After 56% Bounce - simplywall.st
Fri, 21 Mar 2025
OPTN Stock Soars 53% on Inking $330M Deal to be Acquired by Paratek - Yahoo Finance
Thu, 20 Mar 2025
Paratek to buy Optinose for up to $330 million - The Pharma Letter
Thu, 20 Mar 2025
Optinose Cancels Earnings Conference Call Following Acquisition Agreement with Paratek Pharmaceuticals - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers - Specialty & Generic
|
|
| Shares Out | 10 (M) |
| Shares Float | 6 (M) |
| Held by Insiders | 6.3 (%) |
| Held by Institutions | 72.3 (%) |
| Shares Short | 133 (K) |
| Shares Short P.Month | 192 (K) |
| EPS | -2.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -6.06 |
| Profit Margin | -36.6 % |
| Operating Margin | -41.1 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 24.3 % |
| Gross Profit (p.s.) | 7.31 |
| Sales Per Share | 8.08 |
| EBITDA (p.s.) | -1.54 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -34 (M) |
| Levered Free Cash Flow | -8 (M) |
| PE Ratio | -4.43 |
| PEG Ratio | 0 |
| Price to Book value | -1.59 |
| Price to Sales | 1.18 |
| Price to Cash Flow | -2.85 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|